Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/14/2009WO2009060232A1 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
05/14/2009WO2009060226A1 Intranasal compositions
05/14/2009WO2009060218A1 Novel complexes and a process for their preparation
05/14/2009WO2009060215A1 Polyamides
05/14/2009WO2009060209A1 6,6-fused bicyclic aromatic compounds and their therapeuti use
05/14/2009WO2009060206A1 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
05/14/2009WO2009060203A1 3,4,6,7-tetrahydro-1 h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
05/14/2009WO2009060197A1 Imidazopyridazines for use as protein kinase inhibitors
05/14/2009WO2009060186A1 Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias
05/14/2009WO2009060160A1 P38 map kinase inhibitors
05/14/2009WO2009060158A1 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
05/14/2009WO2009060122A2 Use of oligonucleotides with modified bases as antiviral agents
05/14/2009WO2009060114A1 Inhibitors of enzyme o6-alkylguanine-dna-methyltransferase for cancer treatment
05/14/2009WO2009060073A1 Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
05/14/2009WO2009060064A2 Pharmaceutical formulations for the oral administration of ppi
05/14/2009WO2009060063A1 Anthelmintic combination
05/14/2009WO2009060054A1 Triazole derivatives as scd inhibitors
05/14/2009WO2009060053A1 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
05/14/2009WO2009060030A1 Heteroaryl-substituted 2-pyridinylmethylamine derivatives
05/14/2009WO2009059996A1 Prevention and treatment of secondary infections following viral infection
05/14/2009WO2009059989A1 Aqueous emulsions comprising a hydrophobic active ingredient
05/14/2009WO2009059966A1 Therapy option for recoloration of hair via bisphosphonates by physiological repigmentation with age-related and/or premature 'grayed' patients
05/14/2009WO2009059961A2 A method of hormone suppression in humans
05/14/2009WO2009059943A1 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
05/14/2009WO2009059893A1 Crystalline hydrate of betamimetika and use as medicament thereof
05/14/2009WO2009059765A2 Process for the preparation of drospirenone
05/14/2009WO2009059748A2 Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations
05/14/2009WO2009059717A2 Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
05/14/2009WO2009059701A2 Sustained release tablets with hydromorphone
05/14/2009WO2009059690A1 Use of a gestagen in combination with an estrogen and one or more pharmaceutically tolerable excipients/carriers for lactose-free oral contraceptive
05/14/2009WO2009059666A1 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
05/14/2009WO2009059452A1 Tetriacyclodipyranyl coumarins and the anti-hiv and anti-tuberculosis uses thereof
05/14/2009WO2009059448A1 Styrene-acid derivative and use in manufacturing blood-vessel targeted-agent drugs
05/14/2009WO2009059435A1 Avenanthramide-containing compositions
05/14/2009WO2009059425A1 Stat3 inhibitors for the treatment of fibrosis
05/14/2009WO2009059418A1 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
05/14/2009WO2009059415A1 Slow-release device for delivering stabilized honey bee brood pheromone within the hive
05/14/2009WO2009059409A1 Biomarkers for visceral leishmaniasis
05/14/2009WO2009059388A1 Use of antagonists of platelet receptor factor for the treatment of infections caused by the influenza virus
05/14/2009WO2009059350A1 Anti-microbial polymers and their compositions
05/14/2009WO2009042677A3 Stat3 inhibiting compositions and methods
05/14/2009WO2009042632A3 Combination therapy related to serotonin dual action compounds
05/14/2009WO2009042565A3 Inhibitors of eppin/semenogelin binding as male contraceptives
05/14/2009WO2009042444A3 Methods and compounds for treating retinol-related diseases
05/14/2009WO2009039361A3 Process for the preparation of (s)-2-(3-tert-butylureido)-3,3-dimethylbutanoic acid
05/14/2009WO2009039199A3 Compositions comprising stat5 sirna and methods of use thereof
05/14/2009WO2009039189A3 Compositions comprising stat3 sirna and methods of use thereof
05/14/2009WO2009039102A8 Inhibitors of copn (cpn) for the treatment of bacterial infections
05/14/2009WO2009038666A3 Compositions and methods for the identification of inhibitors of retroviral infection
05/14/2009WO2009037357A4 Benzimidazole nf- kappab inhibitors
05/14/2009WO2009036281A3 Bortezomib and process for producing same
05/14/2009WO2009036000A3 Methods of treating a microbial infection by modulating rnase-l expression and/or activity
05/14/2009WO2009035997A3 Benzo-fused heterocycles
05/14/2009WO2009035818A8 Compounds that modulate intracellular calcium
05/14/2009WO2009032930A3 Compositions comprising human integrin-linked kinase-sirna and methods of use thereof
05/14/2009WO2009032158A3 Delayed self-gelling alginate systems and uses thereof
05/14/2009WO2009031040A3 Compounds with anti-cancer activity
05/14/2009WO2009029293A3 Nucleic acid compounds for inhibiting myc gene expression and uses thereof
05/14/2009WO2009027601A3 Pyrazole 3,5 carboxylate derivatives preparation and therapeutic application thereof
05/14/2009WO2009025792A3 Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
05/14/2009WO2009023053A3 Use of rsk inhibitors to impede intracellular pathogen infections
05/14/2009WO2009020987A3 Process for preparation of swellable and degradable microspheres
05/14/2009WO2009019708A3 Pharmaceutical compositions and methods for the treatment of cancer
05/14/2009WO2009018909A3 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
05/14/2009WO2009016350A3 Stimulating gel
05/14/2009WO2009013633A3 Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
05/14/2009WO2009009665A3 O-desmethylvenlafaxine
05/14/2009WO2008156869A3 Sirtuin modulating thiazolopyridine compounds
05/14/2009WO2008144507A3 Spirooxindole inhibitors of aurora kinase
05/14/2009WO2008143729A3 Macrolide compounds and methods of making and using the same
05/14/2009WO2008137816A3 Tricyclic compounds as matrix metalloproteinase inhibitors
05/14/2009WO2008132738A3 Anticancerous polymeric agents
05/14/2009WO2008118823A3 Compositions and methods for inhibition of the jak pathway
05/14/2009WO2008117061A3 Tetrahydroisoquinolines as tumour growth inhibitors
05/14/2009WO2008108742A3 Polymorphic forms of clopidogrel hydrobromide
05/14/2009WO2008088779A3 Solid state forms of 5-azacytidine and processes for preparation thereof
05/14/2009WO2008088415A8 Omega-3 fatty acids for reduction of lp-pla2 levels
05/14/2009WO2008074803A8 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
05/14/2009WO2008068540A8 New benzamide derivatives as bradykinin antagonists
05/14/2009WO2008067378A3 Preparation and utility of substituted phenyltetrazoles
05/14/2009WO2008060626A3 Compounds for modulating trpv3 function
05/14/2009WO2008049123A8 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
05/14/2009WO2008041236A3 Composition comprising crustacean gastrolith components, calcium carbonate and its use
05/14/2009WO2007067711A3 Certain chemical entities, compositions, and methods for modulating trpv1
05/14/2009WO2007059111A3 Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
05/14/2009WO2007054977A3 Method and composition for skin depigmentation
05/14/2009WO2007001399A3 Compositions, splice variants and methods relating to cancer specific genes and proteins
05/14/2009WO2006012624A3 Mechanism-based crosslinkers
05/14/2009WO2005115469A3 Estrogen modulation of ifn-gamma-mediated conditions and diseases
05/14/2009US20090126038 Rna constructs
05/14/2009US20090125331 Methods and systems for treating illnesses
05/14/2009US20090124832 Oligoamine compounds and derivatives thereof for cancer therapy
05/14/2009US20090124831 Lysine-d-amphetamine dimesylate; sustained release of amphetamine; Oral bioavailability of amphetamine maintained at useful doses, but bioavailability at higher dose substantially reduced; attention deficit disorder; hyperacctivity; narcolepsy; obesity; drug abuse, drug dependency
05/14/2009US20090124819 2-substituted vitamin d derivatives
05/14/2009US20090124809 Process for preparing acyclic hcv protease inhibitors
05/14/2009US20090124808 Process for preparing acyclic hcv protease inhibitors
05/14/2009US20090124803 Process for preparation of rosuvastatin
05/14/2009US20090124704 Therapeutic foam
05/14/2009US20090124703 Xanthohumol-enriched hop extract
05/14/2009US20090124702 Pharmaceutical Compositions of Metformin
1 ... 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 ... 7860